Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMA4LNE)

Drug Name
SGN-LIV1A Drug Info
Synonyms Ladiratuzumab Vedotin
Indication
Disease Entry ICD 11 Status REF
Non-small-cell lung cancer 2C25 Phase 2 [1]
Small-cell lung cancer 2C25.Y Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMA4LNE

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Solute carrier family 39 member 6 (SLC39A6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
SGN LIV1A DMVBQ2L Breast cancer 2C60-2C65 Phase 1 [2]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Solute carrier family 39 member 6 (SLC39A6) TTZN1CF S39A6_HUMAN Not Available [2]

References

1 ClinicalTrials.gov (NCT04032704) A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors. U.S. National Institutes of Health.
2 SGN-LIV1A: a novel antibody-drug conjugate targeting LIV-1 for the treatment of metastatic breast cancer. Mol Cancer Ther. 2014 Dec;13(12):2991-3000.